Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Yokota SJ, Facciponte JG, Kelleher RJ Jr, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB.

Cancer Immun. 2013 May 31;13:11. Print 2013.

2.
3.

Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.

Fox LM, Miksanek J, May NA, Scharf L, Lockridge JL, Veerapen N, Besra GS, Adams EJ, Hudson AW, Gumperz JE.

Cancer Immun. 2013 May 10;13:9. Print 2013.

4.

An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, Pulford K, Mufti G, Stevenson F, Guinn BA.

Cancer Immun. 2013 Jul 15;13:16. Print 2013.

5.

Database of T cell-defined human tumor antigens: the 2013 update.

Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P.

Cancer Immun. 2013 Jul 15;13:15. Print 2013. Review.

6.

Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells.

Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, Odunsi K, Bankert RB.

Cancer Immun. 2013 Jul 15;13:14. Print 2013.

7.

Structured reporting of T cell assay results.

Janetzki S, Hoos A, Melief CJ, Odunsi K, Romero P, Britten CM.

Cancer Immun. 2013 Jul 15;13:13. Print 2013. No abstract available.

8.

NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.

von Boehmer L, Mattle M, Bode P, Landshammer A, Schäfer C, Nuber N, Ritter G, Old L, Moch H, Schäfer N, Jäger E, Knuth A, van den Broek M.

Cancer Immun. 2013 Jul 15;13:12. Print 2013.

9.

NKG2D ligands as therapeutic targets.

Spear P, Wu MR, Sentman ML, Sentman CL.

Cancer Immun. 2013 May 1;13:8. Print 2013. Review.

10.

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD.

Cancer Immun. 2013 May 1;13:7. Print 2013.

11.

BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.

Link PA, Zhang W, Odunsi K, Karpf AR.

Cancer Immun. 2013;13:6. Epub 2013 Jan 22.

12.

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso JF, Jure-Kunkel MN.

Cancer Immun. 2013;13:5. Epub 2013 Jan 22. Review.

13.
14.

A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.

Gupta A, Nuber N, Esslinger C, Wittenbrink M, Treder M, Landshammer A, Noguchi T, Kelly M, Gnjatic S, Ritter E, von Boehmer L, Nishikawa H, Shiku H, Old L, Ritter G, Knuth A, van den Broek M.

Cancer Immun. 2013;13:3. Epub 2013 Jan 15.

15.

Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells.

Buckwalter MR, Srivastava PK.

Cancer Immun. 2013;13:2. Epub 2013 Jan 15.

16.

Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K.

Cancer Immun. 2013;13:1. Epub 2013 Jan 15.

17.

MAGE-A3 is highly expressed in a subset of colorectal cancer patients.

Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson AJ, Cordon-Cardo C, Whelan RL.

Cancer Immun. 2012;12:16. Epub 2012 Dec 28.

18.

SurfaceomeDB: a cancer-orientated database for genes encoding cell surface proteins.

de Souza JE, Galante PA, de Almeida RV, da Cunha JP, Ohara DT, Ohno-Machado L, Old LJ, de Souza SJ.

Cancer Immun. 2012;12:15. Epub 2012 Dec 28.

19.

Monoclonal antibodies in cancer therapy.

Scott AM, Allison JP, Wolchok JD.

Cancer Immun. 2012;12:14. Epub 2012 May 1. Review. No abstract available.

20.

Translating basic mechanisms of IgG effector activity into next generation cancer therapies.

Nimmerjahn F, Ravetch JV.

Cancer Immun. 2012;12:13. Epub 2012 May 1. Review.

Supplemental Content

Loading ...
Support Center